Dissoziativa
- ️Fri Nov 03 2017
Literatur
Aan Het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012). Ketamine for depression: Where do we go from here? Biological Psychiatry, 72(7), 537–547.
Aguayo, L. G., Warnick, J. E., Maayani, S., Glick, S. D., Weinstein, H., & Albuquerque, E. X. (1982). Site of action of phencyclidine. IV. Interaction of phencyclidine and its analogues on ionic channels of the electrically excitable membrane and nicotinic receptor: Implications for behavioral effects. Molecular Pharmacology, 21(3), 637–647.
Andreasen, J. T., Gynther, M., Rygaard, A., Bogelund, T., Nielsen, S. D., Clausen, R. P., Mogensen, J., & Pickering, D. S. (2013). Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neuroscience Letters, 546, 6–10.
Anon. (1979). The 1977 street drug analysis results: PharmChem research foundation. Clinical Toxicology, 14(5), 619–630.
Beardsley, P. M., & Balster, R. L. (1987). Behavioral dependence upon phencyclidine and ketamine in the rat. The Journal of Pharmacology and Experimental Therapeutics, 242(1), 203–211.
Bearn, J., & O’Brien, M. (2015). Chapter Ten – „Addicted to euphoria“: The history, clinical presentation, and management of party drug misuse. In A. L. Pille Taba & S. Katrin (Hrsg.), International review of neurobiology (120. Aufl., S. 205–233). San Diego: Academic Press.
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47(4), 351–354.
Bonnet, U. (2015). Long-term ketamine self-injections in major depressive disorder: Focus on tolerance in ketamine’s antidepressant response and the development of ketamine addiction. Journal of Psychoactive Drugs, 47(4), 276–285.
Bowdle, A. T., Radant, A. D., Cowley, D. S., Kharasch, E. D., Strassman, R. J., & Roy-Byrne, P. P. (1998). Psychedelic effects of ketamine in healthy volunteers relationship to steady-state plasma concentrations. The Journal of the American Society of Anesthesiologists, 88(1), 82–88.
Butelman, E. R., & Kreek, M. J. (2015). Salvinorin A, a kappa-opioid receptor agonist hallucinogen: Pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Frontiers in Pharmacology, 6, 190.
Caddy, C., Giaroli, G., White, T. P., Shergill, S. S., & Tracy, D. K. (2014). Ketamine as the prototype glutamatergic antidepressant: Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Therapeutic Advances in Psychopharmacology, 4(2), 75–99.
Connolly, S. B., Prager, J. P., & Harden, R. N. (2015). A systematic review of ketamine for complex regional pain syndrome. Pain Medicine, 16(5), 943–969.
Corazza, O., & Schifano, F. (2010). Near-death states reported in a sample of 50 misusers. Substance Use and Misuse, 45(6), 916–924.
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009). From drugs to deprivation: A Bayesian framework for understanding models of psychosis. Psychopharmacology, 206(4), 515–530.
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011). Glutamatergic model psychoses: Prediction error, learning, and inference. Neuropsychopharmacology, 36(1), 294–315.
Coull, J. T., Morgan, H., Cambridge, V. C., Moore, J. W., Giorlando, F., Adapa, R., … & Fletcher, P. C. (2011). Ketamine perturbs perception of the flow of time in healthy volunteers. Psychopharmacology, 218(3), 543–556.
Curran, H. V., & Morgan, C. (2000). Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction, 95(4), 575–590.
Curran, H. V., & Monaghan, L. (2001). In and out of the K-hole: A comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction, 96(5), 749–760.
Cusin, C., Hilton, G. Q., Nierenberg, A. A., & Fava, M. (2012). Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. The American Journal of Psychiatry, 169(8), 868–869.
DEA. (2014). PCP tablets sold as MDMA. www.justice.gov/archive/ndic/pubs0/661/index.htm. Zugegriffen am 01.08.2016.
Daumann, J., Wagner, D., Heekeren, K., Neukirch, A., Thiel, C. M., & Gouzoulis-Mayfrank, E. (2010). Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. Journal of Psychopharmacology, 24(10), 1515–1524.
Degkwitz, R. (1964). Dextromethorphan (Romilar) as an intoxicating agent. Nervenarzt, 35, 412–414.
Deutsche Hauptstelle für Suchtfragen (DHS). (2015). Bericht 2015 des nationalen REITOX-Knotenpunkts an die EBDD. http://www.dhs.de/fileadmin/user_upload/pdf/Reitox_Jahresberichte/WB03_Drogen_2015_Germany_DE.pdf. Zugegriffen am 01.05.2016.
Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug and Alcohol Dependence, 69(1), 23–28.
Domino, E. F. (2010). Taming the ketamine tiger. The Journal of the American Society of Anesthesiologists, 113(3), 678–684.
Domino, E. F., Chodoff, P., & Corssen, G. (1965). Pharmacologic Effects of Ci-581, a New Dissociative Anesthetic, in Man. Clinical Pharmacology & Therapeutics, 6, 279–291.
Drug Enforcement Administration (DEA). (2014). Office of Diversion Control. Phencyclidine. http://www.deadiversion.usdoj.gov/drug_chem_info/pcp.pdf. Zugegriffen am 01.05.2016.
Ebert, B., Mikkelsen, S., Thorkildsen, C., & Borgbjerg, F. M. (1997). Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. European Journal of Pharmacology, 333(1), 99–104.
Erdemir, H., Huber, F. C., & Corssen, G. (1970). Dissociative anesthesia with ketamine: A suitable adjunct to epidural anesthesia. Anesthesia & Analgesia, 49(4), 623–627.
Fontana y Col, A. E. (1974). Terapia antidepresiva con CI 581 (Ketamina) Acta Psiquiat. Psicol. America Latina.
Geschwinde, T. (2013). Rauschdrogen: Marktformen und Wirkungsweisen. Berlin: Springer.
Giannini, A. J., Underwood, N. A., & Condon, M. (2000). Acute ketamine intoxication treated by haloperidol: A preliminary study. American Journal of Therapy, 7(6), 389–391.
Giorgetti, R., Marcotulli, D., Tagliabracci, A., & Schifano, F. (2015). Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability. Forensic Science International, 252, 127–142.
Golechha, G. R., Sethi, I. C., Misra, S. L., & Jayaprakash, N. P. (1986). Ketamine abreaction: A new approach to narcoanalysis. Indian Journal of Psychiatry, 28(4), 297.
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K. A. (2005). Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry, 38(6), 301–311.
Green, S. M., Rothrock, S. G., Harris, T., Hopkins, G. A., Garrett, W., & Sherwin, T. (1998). Intravenous ketamine for pediatric sedation in the emergency department: Safety profile with 156 cases. Academic Emergency Medicine, 5(10), 971–976.
Gutkin, E., Hussain, S. A., & Kim, S. H. (2012). Ketamine-induced biliary dilatation: From Hong Kong to New York. Journal of Addiction Medicine, 6(1), 89–91.
Hinsberger, A., Sharma, V., & Mazmanian, D. (1994). Cognitive deterioration from long-term abuse of dextromethorphan: A case report. Journal of Psychiatry and Neuroscience, 19(5), 375–377.
Huang, M. C., Chen, L. Y., Chen, C. K., & Lin, S. K. (2016). Potential benefit of lamotrigine in managing ketamine use disorder. Medical Hypotheses, 87, 97–100.
Jansen, K. L. (1993). Non-medical use of ketamine. British Medical Journal, 306(6878), 601–602.
Jansen, K. L., & Sferios, E. (2001). Ketamine: Dreams and realities. Sarasota: Multidisciplinary Association for Psychedelic Studies.
Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2011). Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug and Alcohol Dependence, 115(1–2), 150–155.
Kampman, K. M. (2002). Amantadine treatment for cocaine-dependent patients with severe withdrawal symptoms. Expert Review of Neurotherapeutics, 2(5), 601–608.
Kettner, A., Schröder, K., & Graubaum, D. Drug Scouts. http://drugscouts.de/de/lexikon/ketamin. Zugegriffen am 10. 12. 2016.
Klein, P. S., & Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences of the United States of America, 93(16), 8455–8459.
Knoche, E., Traub, E., & Dick, W. (1978). Möglichkeiten der medikamentösen Beeinflussung von unerwünschten Nebenwirkungen und Aufwachreaktionen nach Ketamin-Anaesthesie. Anaesthesist, 27, 302.
Kohler, S., & Betzler, F. (2015). Ketamine – A new treatment option for therapy-resistant depression. Fortschritte der Neurologie-Psychiatrie, 83(2), 91–97.
Kohrs, R., & Durieux, M. E. (1998). Ketamine: Teaching an old drug new tricks. Anesthesia and Analgesia, 87(5), 1186–1193.
Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs, 29(2), 165–183.
Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., Heninger, G. R., Bowers, M. B., & Charney, D. S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51(3), 199–214.
Lahti, A. C., Koffel, B., LaPorte, D., & Tamminga, C. A. (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 13(1), 9–19.
Larkin, G. L., & Beautrais, A. L. (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology, 14(8), 1127–1131.
Leuner, H. (1981). Halluzinogene: Psychische Grenzzustände in Forschung und Psychotherapie. Bern: Huber.
Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M. I., Li, X. Y., Aghajanian, G., & Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964.
Li, N., Liu, R. J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X. Y., Aghajanian, G., & Duman, R. S. (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biological Psychiatry, 69(8), 754–761.
Lilly, J. C. (1978). The scientist: A novel autobiography. Philadelphia: Lippincott Williams & Wilkins.
Liu, Y., Lin, D., Wu, B., & Zhou, W. (2016). Ketamine abuse potential and use disorder. Brain Research Bulletin, 126, 68–73.
Lundberg, G. D., Gupta, R. C., & Montgomery, S. H. (1976). Phencyclidine: Patterns seen in street drug analysis. Clinical Toxicology, 9(4), 503–511.
Ma, X. C., Dang, Y. H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C. G., & Hashimoto, K. (2013). Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One, 8(2), e56053.
Maddox, V. H. (1981). The historical development of phencyclidine. In E. F. Domino (Hrsg.), PCP (Phencyclidine): Historical and current perspectives (S. 1–8). Michigan: NPP Books.
Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar, D., & Breier, A. (1996). NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14(5), 301–307.
Mathew, S. J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., & Murrough, J. W. (2012). Ketamine for treatment-resistant unipolar depression. CNS Drugs, 26(3), 189–204.
McCambridge, J., Winstock, A., Hunt, N., & Mitcheson, L. (2007). 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. European Addiction Research, 13(1), 57–64.
McEwen, B. S. (2008). Central effects of stress hormones in health and disease: Understanding the protective and damaging effects of stress and stress mediators. European Journal of Pharmacology, 583(2–3), 174–185.
Mercadante, S. (2015). Topical amitriptyline and ketamine for the treatment of neuropathic pain. Expert Review of Neurotherapeutics, 15(11), 1249–1253.
Meyer, M. R., & Maurer, H. H. (2011). Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics, 12(2), 215–233.
Monteggia, L. M., Gideons, E., & Kavalali, E. T. (2013). The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biological Psychiatry, 73(12), 1199–1203.
Moore, M., & Alltounian, H. S. (1978). Journeys into the bright world. San Francisco: Para Research.
Morgan, C. J., & Curran, H. V. (2006). Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology, 188(4), 408–424.
Morgan, C. J., & Curran, H. V. (2012). Ketamine use: A review. Addiction, 107(1), 27–38.
Morgan, C. J., Muetzelfeldt, L., & Curran, H. V. (2010). Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study. Addiction, 105(1), 121–133.
Morgan, H. L., Turner, D. C., Corlett, P. R., Absalom, A. R., Adapa, R., Arana, F. S., Pigott, J., Gardner, J., Everitt, J., Haggard, P., & Fletcher, P. C. (2011). Exploring the impact of ketamine on the experience of illusory body ownership. Biological Psychiatry, 69(1), 35–41.
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632.
Muetzelfeldt, L., Kamboj, S. K., Rees, H., Taylor, J., Morgan, C. J. A., & Curran, H. V. (2008). Journey through the K-hole: Phenomenological aspects of ketamine use. Drug and Alcohol Dependence, 95(3), 219–229.
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., Charney, D. S., & Mathew, S. J. (2013). Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. American Journal of Psychiatry, 170(10), 1134–1142.
Mutschler, J., Koopmann, A., Grosshans, M., Hermann, D., Mann, K., & Kiefer, F. (2010). Dextromethorphan withdrawal and dependence syndrome. Deutsches Ärzteblatt International, 107(30), 537–540.
Ng, S. H., Tse, M. L., Ng, H. W., & Lau, F. L. (2010). Emergency department presentation of ketamine abusers in Hong Kong: A review of 233 cases. Hong Kong Medical Journal, 16(1), 6–11.
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369(9566), 1047–1053.
O’Neill, M. J., Bleakman, D., Zimmerman, D. M., & Nisenbaum, E. S. (2004). AMPA receptor potentiators for the treatment of CNS disorders. Current Drug Targets. CNS and Neurological Disorders, 3(3), 181–194.
Passie, T., Karst, M., Borsutzky, M., Wiese, B., Emrich, H. M., & Schneider, U. (2003). Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man. Journal of Psychopharmacology, 17(1), 51–56.
Passie, T., Karst, M., Wiese, B., Emrich, H. M., & Schneider, U. (2005). Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology, 51(4), 226–233.
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016). Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clinical Pharmacokinetics, 55(9), 1059–1077.
Perel, A., & Davidson, J. T. (1976). Recurrent hallucinations following ketamine. Anaesthesia, 31(8), 1081–1083.
Pioro, E. P., Brooks, B. R., Cummings, J., Schiffer, R., Thisted, R. A., Wynn, D., Hepner, A., & Kaye, R. (2010). Dextromethorphan plus ultra Low-Dose quinidine reduces pseudobulbar affect. Annals of Neurology, 68(5), 693–702.
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry, 66(5), 522–526.
Priestley, S. J., Taylor, J., McAdam, C. M., & Francis, P. (2001). Ketamine sedation for children in the emergency department. Emergency Medicine (Fremantle, W.A.), 13(1), 82–90.
Reier, C. E. (1971). Ketamine – „dissociative agent“ or hallucinogen? New England Journal of Medicine, 284(14), 791–792.
Roche Products Ltd. (1952). The resolution of 3-hydroxy- and 3-methoxyN-methyl-morphinanes and process for the manufacture of the latter.
Scheidegger, M., Walter, M., Lehmann, M., Metzger, C., Grimm, S., Boeker, H., & Seifritz, E. (2012). Ketamine decreases resting state functional network connectivity in healthy subjects: Implications for antidepressant drug action. PloS One, 7(9), e44799.
Scherbaum, N., Schifano, F., & Siemann, H. (2014). Neue psychotrope Substanzen – „Legal Highs“. Fortschritte der Neurologie Psychiatrie, 82(09), 532–543.
Scholler, K. L., Thies, H., & Wiemers, K. (1960). General anesthesia with cyclohexylamine derivatives, clinical observations and electroencephalographic studies. Anaesthesist, 9, 163–169.
Shahani, R., Streutker, C., Dickson, B., & Stewart, R. J. (2007). Ketamine-associated ulcerative cystitis: A new clinical entity. Urology, 69(5), 810–812.
Shansky, R. M., & Morrison, J. H. (2009). Stress-induced dendritic remodeling in the medial prefrontal cortex: Effects of circuit, hormones and rest. Brain Research, 1293, 108–113.
Skeldon, S. C., & Goldenberg, S. L. (2014). Urological complications of illicit drug use. Nature Reviews. Urology, 11(3), 169–177.
Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). PloS one, 5(8), e12412.
Substance Abuse and Mental Health Services Administration (SAMHSA). (2008). The NSDUH Report – Use of specific hallucinogens. 2006. Rockville: NSDUH.
Sunder, R. A., Toshniwal, G., & Dureja, G. P. (2008). Ketamine as an adjuvant in sympathetic blocks for management of central sensitization following peripheral nerve injury. Journal of Brachial Plexus and Peripheral Nerve Injury, 3, 22.
Umbricht, D., Schmid, L., Koller, R., Vollenweider, F. X., Hell, D., & Javitt, D. C. (2000). Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry, 57(12), 1139–1147.
UNODC. (2010). World drug report 2010. New York.
UNODC. (2014). 2014 Global synthetic drugs assessment (United Nations Publication, Sales No. E.14.XI.6).
Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Review Neuroscience, 11(9), 642–651.
White, J. M., & Ryan, C. F. (1996). Pharmacological properties of ketamine. Drug and Alcohol Review, 15(2), 145–155.
Wilkins, L. K., Girard, T. A., & Cheyne, J. A. (2011). Ketamine as a primary predictor of out-of-body experiences associated with multiple substance use. Consciousness and Cognition, 20(3), 943–950.
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., Dossou, K. S., Fang, Y., Huang, X. P., Mayo, C. L., Wainer, I. W., Albuquerque, E. X., Thompson, S. M., Thomas, C. J., Zarate, C. A., Jr., & Gould, T. D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481–486.
Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63(8), 856–864.
Zarate, C. A., Jr., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012). Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry, 71(11), 939–946.
Zielmann, S., Kazmaier, S., Schnüll, S., & Weyland, A. (1997). S-(+)-Ketamine and circulation. Anaesthesist, 46(Suppl 1), S43–S46.